Showing 15 posts of 79 posts found.

GSK says asthma drug Breo shows superior results over standard care in major study

May 24, 2016
Research and Development, Sales and Marketing COPD, GSK, asthma, breo, drug trial

UK drugmaker GlaxoSmithKline (LSE: GSK) on Tuesday said inhaled medicine Breo proved significantly better than standard care in a major …


AstraZeneca’s COPD therapy gets US FDA approval

April 26, 2016
Research and Development, Sales and Marketing AstraZeneca, COPD, US FDA, drug approval

UK drug firm AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved its therapy to treat chronic …


AstraZeneca buys rights to Orexo respiratory programme

March 21, 2016
Sales and Marketing AstraZeneca, COPD, asthma, orexo

AstraZeneca has bought the rights to a respiratory programme from Sweden’s Orexo for $5 million. The deal centres on the …

Novartis image

Novartis and Qualcomm to develop smart inhaler technology for COPD

January 8, 2016
Manufacturing and Production, Medical Communications COPD, Novartis, Qualcomm Life, breezhaler, digital inhaler, qualcomm

Novartis has enlisted Qualcomm life to help the pharma giant develop the ‘next generation’ of its Breezhaler device for patients …

Propeller Health smart inhaler

GSK collaborates on ‘smart inhaler’ technology for respiratory trials

December 3, 2015
Research and Development COPD, GSK, Propeller, Propeller Health, asthma, clinical trials, ellipta, inhalers, smart drugs, smart inhalers

GSK has entered the ‘smart drug’ industry by partnering with a health technology company to develop a sensor for use …


Verona Pharma’s respiratory drug proves positive in study

October 1, 2015
Research and Development COPD, verona pharma

Verona Pharma has announced encouraging positive headline data of the third and final part of a randomised, clinical study in …


Genetic study reveals new associations with lung disease and smoking behaviour

September 25, 2015
Medical Communications, Research and Development COPD, lung cancer, smkoing

New research published in The Lancet Respiratory Medicine and presented at this year’s European Respiratory Society (ERS) Congress in Amsterdam …

BI building

Boehringer and BioMed X crowdsource top scientists to fight COPD

September 23, 2015
Research and Development Boehringer Ingelheim, COPD

Boehringer Ingelheim and BioMed X have used a crowdsourcing strategy to establish a global research team to collaborate on the …

asthma inhalers

GSK suffers Breo late-stage trial blow

September 9, 2015
Research and Development COPD, GSK, Revlar, asthma, breo, clinical trial, phase III

GSK has hit a setback in its plans to expand sales of its blockbuster asthma treatment Breo, after a major …

MRC, GSK and universities team up on inflammatory diseases

July 15, 2015
Research and Development COPD, GSK, MRC, Medical Research Council, fibrosis, inflammatory diseases

UK pharma giant GSK is partnering with the Medical Research Council, to study the biological mechanisms behind common inflammatory diseases. …

BI building

Boehringer Ingelheim launches Spiolto for COPD

July 2, 2015
Sales and Marketing Boehringer Ingelheim, COPD, Europe, Spiolto, Spiriva, Striverdi

Boehringer Ingelheim is beginning a new push in lung disease across Europe after being approved by regulators in nine countries …

Boehringer assures future growth following sales drop

April 23, 2015
Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results

Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …

AZ image

AstraZeneca completes respiratory deal with Actavis

March 3, 2015
Research and Development, Sales and Marketing Actavis, AstraZeneca, COPD, Daliresp, Tudorza Pressair, aclidinium bromide inhalation powder, respiratory, roflumilast

AstraZeneca has completed its acquisition of Dublin-headquartered firm Actavis with its branded respiratory portfolio deal worth $700 million. The agreement …

GSK image

Second late-stage COPD trial for GSK and Theravance

February 10, 2015
Sales and Marketing COPD, FF/UMEC/VI, GSK, Theravance, fluticasone furoate, umeclidinium, vilanterol

GlaxoSmithKline and Theravance have begun a second Phase III trial of their investigational triple combination COPD drug as the former …

Latest content